{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T17:58:41Z","timestamp":1782755921834,"version":"3.54.5"},"reference-count":60,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021281","name":"Gates Family Foundation","doi-asserted-by":"publisher","award":["INV-034993"],"award-info":[{"award-number":["INV-034993"]}],"id":[{"id":"10.13039\/100021281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Human papillomavirus (HPV) infection is a primary cause of preventable deaths from cervical cancer, a condition of profound inequality with approximately 90% of deaths occurring in low- and middle-income countries, particularly in sub-Saharan Africa. In May 2018, the WHO Director-General declared a Joint Global Commitment to Cervical Cancer Elimination, highlighting the critical role of HPV vaccines in achieving this goal. However, there is a lack of systemically collected data on HPV prevalence in The Gambia, and impact data from high-income countries may not be reliably extrapolated to West African settings due to geographical variation in HPV types and distinct behavioural, biological, and sociodemographic exposures. The Gambia introduced a two-dose HPV vaccination schedule in 2019, but coverage has been very low, interrupted mainly by the COVID-19 pandemic. This presents a key opportunity to generate vital baseline data on HPV prevalence in the population before potential scale-up of vaccination efforts. The PHASE survey, a multi-stage cluster survey, aims to establish the baseline, population prevalence estimates of high-risk and low-risk, vaccine-type and non-vaccine-type HPV infection in 15- to 49-year-old females in The Gambia by measuring urinary HPV-DNA. The survey will also quantify the effects of various exposures on HPV prevalence, including sexual behaviour, the presence of other sexually-transmitted infections (STIs) - Neisseria gonorrhoea (NG), Chlamydia trachomatis (CT), Trichomonas vaginalis (TV), Mycoplasma genitalium (MG), syphilis, as well as blood borne viruses, human immunodeficiency virus (HIV), hepatitis B and hepatitis C; obstetric history, socio-demographic characteristics, and cervical cancer screening and\/or treatment. Additionally, the study will provide important antimicrobial resistance (AMR) data for NG and MG in sub-Saharan Africa, a region poorly represented in global surveillance programs. This data is needed to guide regional treatment guidelines and advocate for new solutions, including gonococcal vaccines. The AMR data are expected to immediately influence recommendations regarding the appropriate choice of antibiotics for syndromic STI management in West Africa and hence to address an important driver of AMR in the sub-region. Leveraging on the Medical Research Council Unit The Gambia funded Health Demographic Surveillance system (HDSS) as its sampling frame, the survey will utilize validated diagnostic assays and culturally sensitive data collection methods, to ensure both scientific rigor and local relevance. Tools such as Audio Computer-Assisted Self-Interviewing (ACASI) technology, developed in consultation with local community advisory boards, are included to reduce social desirability bias in reporting sexual behaviour. This approach aims to maximize both the reliability and cultural appropriateness of the findings. This study directly addresses the critical need for baseline epidemiological data on HPV in a West African setting to accelerate vaccine impact and drive new interventions towards cervical cancer elimination. By understanding other factors that influence HPV (like other STIs, sexual behaviour, etc.), the study aims to ensure that, when the vaccine\u2019s impact is measured later, changes in other confounding factors that may impact on HPV prevalence can be accounted for. The study will also establish the population prevalence of the measured STIs and their relationship to common symptoms and other adverse health outcomes related to STIs.<\/jats:p>","DOI":"10.1371\/journal.pone.0332842","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T17:28:58Z","timestamp":1758562138000},"page":"e0332842","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Human papillomavirus, sexually transmitted infections, and antimicrobial resistance in West Africa: Estimating population burden and understanding exposures to accelerate vaccine impact and drive new interventions: The PHASE survey protocol"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0532-3648","authenticated-orcid":true,"given":"Adedapo Olufemi","family":"Bashorun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2640-9456","authenticated-orcid":true,"given":"Larry","family":"Kotei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdoulie F.","family":"Jallow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ousubie","family":"Jawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel U.","family":"Richard-Ugwuadu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"Jagana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamin","family":"Bah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amadou Tijan","family":"Bah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karamo","family":"Conteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamadou S.K.","family":"Jallow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrab","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bai Lamin","family":"Dondeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Segonds-Pichon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary M.","family":"Clifford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Baussano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Pichon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jeffries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"issue":"6","key":"pone.0332842.ref001","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"F Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"pone.0332842.ref002","doi-asserted-by":"crossref","DOI":"10.3390\/v15071440","article-title":"Recent developments in human papillomavirus (HPV) vaccinology","volume":"15","author":"AL Williamson","year":"2023","journal-title":"Viruses"},{"key":"pone.0332842.ref003","unstructured":"Human papillomavirus vaccines: WHO position (2022) [Internet]. 2022. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/365350\/WER9750-eng-fre.pdf?sequence=1"},{"issue":"11","key":"pone.0332842.ref004","article-title":"Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males","volume":"2019","author":"H Bergman","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0332842.ref005","doi-asserted-by":"crossref","first-page":"100486","DOI":"10.1016\/j.jvacx.2024.100486","article-title":"Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to multidose vaccination regimens or no vaccination: An updated systematic review of evidence from clinical trials","volume":"19","author":"HS Whitworth","year":"2024","journal-title":"Vaccine X"},{"issue":"1","key":"pone.0332842.ref006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0290808","article-title":"The clinical effectiveness of one-dose vaccination with an HPV vaccine: A meta-analysis of 902,368 vaccinated women","volume":"19","author":"D Setiawan","year":"2024","journal-title":"PLoS One"},{"issue":"3","key":"pone.0332842.ref007","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(23)00586-7","article-title":"Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose in young women aged 15-20 years in Kenya (KEN SHE): an immunobridging analysis of randomised controlled trials","volume":"12","author":"K Baisley","year":"2024","journal-title":"Lancet Glob Health"},{"issue":"12","key":"pone.0332842.ref008","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S1470-2045(20)30524-6","article-title":"Efficacy of the bivalent HPV vaccine against HPV 16\/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial","volume":"21","author":"C Porras","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"pone.0332842.ref009","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1470-2045(15)00047-9","article-title":"Efficacy of fewer than three doses of an HPV-16\/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials","volume":"16","author":"AR Kreimer","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"pone.0332842.ref010","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.vaccine.2022.11.044","article-title":"Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination","volume":"41","author":"S Joshi","year":"2023","journal-title":"Vaccine"},{"issue":"11","key":"pone.0332842.ref011","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S1470-2045(21)00453-8","article-title":"Vaccine efficacy against persistent human papillomavirus (HPV) 16\/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study","volume":"22","author":"P Basu","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"pone.0332842.ref012","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/cid\/ciz239","article-title":"Dose-related Effectiveness of Quadrivalent Human Papillomavirus Vaccine Against Cervical Intraepithelial Neoplasia: A Danish Nationwide Cohort Study","volume":"70","author":"F Verdoodt","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"10197","key":"pone.0332842.ref013","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"M Drolet","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"pone.0332842.ref014","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.3201\/eid2210.160675","article-title":"Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes","volume":"22","author":"D Mesher","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"pone.0332842.ref015","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1016\/j.vaccine.2018.01.057","article-title":"Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs","volume":"36","author":"LE Markowitz","year":"2018","journal-title":"Vaccine"},{"issue":"1","key":"pone.0332842.ref016","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-2667(18)30189-0","article-title":"Modelling cervical cancer elimination","volume":"4","author":"I Baussano","year":"2019","journal-title":"Lancet Public Health"},{"issue":"11","key":"pone.0332842.ref017","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1099\/jmm.0.000848","article-title":"Human papilloma virus genotype distribution and risk factor analysis amongst reproductive-age women in urban Gambia","volume":"67","author":"H Bah Camara","year":"2018","journal-title":"J Med Microbiol"},{"issue":"9","key":"pone.0332842.ref018","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/sj.bjc.6602736","article-title":"Cervical human papillomavirus infection and squamous intraepithelial lesions in rural Gambia, West Africa: viral sequence analysis and epidemiology","volume":"93","author":"SR Wall","year":"2005","journal-title":"Br J Cancer"},{"key":"pone.0332842.ref019","unstructured":"WHO. Strategic Advisory Group of Experts (SAGE) in Immunization. Working group on potential contribution of human papillomavirus (HPV) vaccines and immunization towards cervical cancer elimination. Background documents and report to SAGE. 201904 Jan 2021. Available from: https:\/\/www.who.int\/immunization\/sage\/meetings\/2019\/october\/1_HPV_SAGE2019WG_for_SAGE.pdf"},{"key":"pone.0332842.ref020","unstructured":"WHO. One-dose Human Papillomavirus (HPV) vaccine offers solid protection against cervical cancer 2022 [Available from: https:\/\/www.who.int\/news\/item\/11-04-2022-one-dose-human-papillomavirus-(hpv)-vaccine-offers-solid-protection-against-cervical-cancer"},{"key":"pone.0332842.ref021","unstructured":"World Health Organization. HPV vaccine included in national immunization programme 2025 [updated 04Feb202520Mar2025]. Available from: https:\/\/app.powerbi.com\/view?r=eyJrIjoiNDIxZTFkZGUtMDQ1Ny00MDZkLThiZDktYWFlYTdkOGU2NDcwIiwidCI6ImY2MTBjMGI3LWJkMjQtNGIzOS04MTBiLTNkYzI4MGFmYjU5MCIsImMiOjh9&disablecdnExpiration=1718064321"},{"key":"pone.0332842.ref022","unstructured":"WHO. Progress report on HIV, viral hepatitis and sexually transmitted infections, 2019. Accountability for the global health sector strategies, 2016-202103 Jan 2021. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/324797\/WHO-CDS-HIV-19.7-eng.pdf?ua=1"},{"issue":"8","key":"pone.0332842.ref023","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(17)30310-9","article-title":"Sexually transmitted infections: challenges ahead","volume":"17","author":"M Unemo","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"pone.0332842.ref024","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1473-3099(18)30225-1","article-title":"Public health surveillance of multidrug-resistant clones of Neisseria gonorrhoeae in Europe: a genomic survey","volume":"18","author":"SR Harris","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"pone.0332842.ref025","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/S1473-3099(20)30154-7","article-title":"Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis","volume":"20","author":"DA Machalek","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"pone.0332842.ref026","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1071\/SH19060","article-title":"Advancing vaccine development for gonorrhoea and the Global STI Vaccine Roadmap","volume":"16","author":"SL Gottlieb","year":"2019","journal-title":"Sex Health"},{"key":"pone.0332842.ref027","volume-title":"The Gambia 2024 Population and Housing Census - Preliminary report","author":"Gambia Bureau of Statistics","year":"2024"},{"key":"pone.0332842.ref028","volume-title":"The Gambia Demographic and Health Survey 2019-20","author":"Gambia Bureau of Statistics - GBoS, ICF","year":"2021"},{"issue":"3","key":"pone.0332842.ref029","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/sextrans-2015-052060","article-title":"Population-based survey on STI-associated symptoms and health-seeking behaviours among Iranian adults","volume":"92","author":"M Nasirian","year":"2016","journal-title":"Sex Transm Infect"},{"issue":"5","key":"pone.0332842.ref030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0001626","article-title":"Nearly half of adults with symptoms of sexually transmitted infections (STIs) did not seek clinical care: A population-based study of treatment-seeking behavior among adults in Rakai, Uganda","volume":"3","author":"YP Ogale","year":"2023","journal-title":"PLOS Glob Public Health"},{"key":"pone.0332842.ref031","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10461-018-2130-5","article-title":"Symptom-Based Versus Laboratory-Based Diagnosis of Five Sexually Transmitted Infections in Female Sex Workers in Iran","volume":"22","author":"A Shahesmaeili","year":"2018","journal-title":"AIDS Behav"},{"key":"pone.0332842.ref032","unstructured":"Guidelines For The Management Of Symptomatic Sexually Transmitted Infections \u2013 WHO, June 202123 Sep 2023. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240024168"},{"key":"pone.0332842.ref033","unstructured":"Sexually Transmitted Infections Treatment Guidelines \u2013 CDC, 2021. Available from: https:\/\/www.cdc.gov\/std\/treatment-guidelines\/default.htm"},{"issue":"4","key":"pone.0332842.ref034","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1086\/381395","article-title":"Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men","volume":"189","author":"BA Weaver","year":"2004","journal-title":"J Infect Dis"},{"issue":"8","key":"pone.0332842.ref035","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1086\/521629","article-title":"The optimal anatomic sites for sampling heterosexual men for human papillomavirus (HPV) detection: the HPV detection in men study","volume":"196","author":"AR Giuliano","year":"2007","journal-title":"J Infect Dis"},{"issue":"1","key":"pone.0332842.ref036","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1128\/JCM.01576-06","article-title":"Penile, urethral, and seminal sampling for diagnosis of human papillomavirus infection in men","volume":"45","author":"L Giovannelli","year":"2007","journal-title":"J Clin Microbiol"},{"key":"pone.0332842.ref037","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g5542","article-title":"Urine testing for HPV","volume":"349","author":"HC Kitchener","year":"2014","journal-title":"BMJ"},{"key":"pone.0332842.ref038","article-title":"Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis","volume":"349","author":"N Pathak","year":"2014","journal-title":"BMJ (Clinical research ed)"},{"key":"pone.0332842.ref039","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g6252","article-title":"Urine testing for HPV: rationale for using first void","volume":"349","author":"A Vorsters","year":"2014","journal-title":"BMJ"},{"issue":"11","key":"pone.0332842.ref040","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s10096-014-2147-2","article-title":"Optimization of HPV DNA detection in urine by improving collection, storage, and extraction","volume":"33","author":"A Vorsters","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"pone.0332842.ref041","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.01404-24","article-title":"Optimization and analytical validation of the Allplex HPV28 genotyping assay for use in first-void urine samples","volume":"63","author":"M Bell","year":"2025","journal-title":"J Clin Microbiol"},{"issue":"8","key":"pone.0332842.ref042","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1128\/JCM.00618-16","article-title":"Comparison of Two Widely Used Human Papillomavirus Detection and Genotyping Methods, GP5+\/6+-Based PCR Followed by Reverse Line Blot Hybridization and Multiplex Type-Specific E7-Based PCR","volume":"54","author":"GM Clifford","year":"2016","journal-title":"J Clin Microbiol"},{"key":"pone.0332842.ref043","unstructured":"WHO. Point-of-care tests for sexually transmitted infections: target product profiles; 18 July 20223 [Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240077102"},{"key":"pone.0332842.ref044","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1130762","article-title":"Mycoplasma genitalium prevalence, antimicrobial resistance-associated mutations, and coinfections with non-viral sexually transmitted infections in high-risk populations in Guatemala, Malta, Morocco, Peru and South Africa, 2019\u20132021","volume":"14","author":"E Shipitsyna","year":"2023","journal-title":"Frontiers in Microbiology"},{"issue":"1","key":"pone.0332842.ref045","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12879-019-3797-6","article-title":"Macrolide and fluoroquinolone resistance-associated mutations in Mycoplasma genitalium in Johannesburg, South Africa, 2007\u20132014","volume":"19","author":"EE Muller","year":"2019","journal-title":"BMC Infectious Diseases"},{"issue":"11","key":"pone.0332842.ref046","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/S1473-3099(20)30154-7","article-title":"Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis","volume":"20","author":"DA Machalek","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"pone.0332842.ref047","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2307\/2531060","article-title":"A Comparison of Confidence Interval Methods for the Intraclass Correlation Coefficient","volume":"42","author":"A Donner","year":"1986","journal-title":"Biometrics"},{"key":"pone.0332842.ref048","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/1471-2288-14-121","article-title":"Comparison of confidence interval methods for an intra-class correlation coefficient (ICC)","volume":"14","author":"AC Ionan","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"7","key":"pone.0332842.ref049","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/sim.3523","article-title":"Confidence interval construction for a difference between two dependent intraclass correlation coefficients","volume":"28","author":"CF Ramasundarahettige","year":"2009","journal-title":"Stat Med"},{"issue":"1","key":"pone.0332842.ref050","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1186\/s12879-020-05663-7","article-title":"Urine collection in cervical cancer screening - analytical comparison of two HPV DNA assays","volume":"20","author":"M Tranberg","year":"2020","journal-title":"BMC Infect Dis"},{"key":"pone.0332842.ref051","unstructured":"WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition. 06 July 202119 Sep 2023. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240030824"},{"issue":"4","key":"pone.0332842.ref052","article-title":"Clinical performance of a newly developed domestic urine-based HPV test for cervical cancer screening in China","volume":"95","author":"H-F Xu","year":"2023","journal-title":"J Med Virol"},{"key":"pone.0332842.ref053","unstructured":"ISRCTN13132810; Urine human papillomavirus (HPV) testing for cervical pre-cancer screening [Available from: https:\/\/www.isrctn.com\/ISRCTN13132810"},{"issue":"3","key":"pone.0332842.ref054","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/annonc\/mdp471","article-title":"European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition--summary document","volume":"21","author":"M Arbyn","year":"2010","journal-title":"Ann Oncol"},{"issue":"7","key":"pone.0332842.ref055","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/bjc.2011.30","article-title":"HPV type-specific prevalence using a urine assay in unvaccinated male and female 11- to 18-year olds in Scotland","volume":"104","author":"MC O\u2019Leary","year":"2011","journal-title":"Br J Cancer"},{"issue":"7","key":"pone.0332842.ref056","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/sextrans-2011-050211","article-title":"Acceptability and response to a postal survey using self-taken samples for HPV vaccine impact monitoring","volume":"87","author":"K Sinka","year":"2011","journal-title":"Sex Transm Infect"},{"key":"pone.0332842.ref057","unstructured":"Biological agents. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1\u2013441."},{"issue":"10451","key":"pone.0332842.ref058","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0140-6736(24)01097-3","article-title":"Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature","volume":"404","author":"F Wei","year":"2024","journal-title":"Lancet"},{"issue":"9596","key":"pone.0332842.ref059","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"E von Elm","year":"2007","journal-title":"Lancet"},{"key":"pone.0332842.ref060","unstructured":"ICMJE. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals [Available from: http:\/\/www.icmje.org\/icmje-recommendations.pdf"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0332842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T17:29:13Z","timestamp":1758562153000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0332842"}},"subtitle":[],"editor":[{"given":"Katrien G.","family":"Janin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":60,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0332842","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]}}}